• KOLs Community
    • Pancreatic
    • Pancreatic Cancer
    • Pancreatic Cancer Cells
    • Ugur Akar
    • Ugur Akar

      Ugur Akar

      Department of Breast Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX. | Department of Breast Medical Oncology, The University of Texas M.D. ...



      KOL Resume for Ugur Akar


      Department of Breast Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX.


      Department of Breast Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA


      Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, Texas 77030, USA


      Department of Experimental Therapeutics, Unit 422, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA


      Authors' Affiliations: Breast Cancer Translational Research Laboratory, Departments of Breast Medical Oncology, Biostatistics, Pathology, and Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, Texas; and Department of Obstetrics and Gynecology, Tottori University School of Medicine, Yonago, Japan

      Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1354, 77030-4009, Houston, TX, USA


      Authors' Affiliations: 1Breast Cancer Translational Research Laboratory, 2Department of Breast Medical Oncology, 3Department of Experimental Therapeutics, and 4Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M. D. Anderson Cancer Center, Houston, Texas


      Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.


      Department of Experimental Therapeutics, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA.


      Experimental Therapeutics, MD Anderson Cancer Center, Houston, TX, USA


      Istanbul Medical Faculty, Department of Medical Biology, Istanbul, Turkey


      From the Departments of Dermatologya and Medical Biology,b Istanbul Medical Faculty, Istanbul University.


      Istanbul School of Dentistry, Istanbul, and, Division of Nephrology, Department of Internal Medicine, and, Department of Medical Biology, Istanbul School of Medicine, Istanbul, Turkey


      *Institute of Child Health, University of Istanbul



      Ugur Akar: Influence Statistics

      Sample of concepts for which Ugur Akar is among the top experts in the world.
      Concept World rank
      cells type brca #4
      mitophagy brca1 #4
      melanoma proliferation zyflamend #4
      atoinduced apoptosis apl #4
      dap5 p97 granulocytes #4
      loss azd2281 #4
      dap5 p97 differentiation #4
      dap5 p97 protein #4
      zyflamend autophagy blotting #4
      olaparib autophagy mitophagy #4
      zyflamend melanoma #4
      apl regulatory #4
      acute models regulation #4
      dap5 p97 inhibition #4
      zyflamend melanoma proliferation #4
      brca1 autophagy brca1 #4
      p97 differentiation #4
      zyflamend mediates #4
      factor4 granulocytes #4
      autophagy mitophagy brca1 #4
      brca allelic #4
      supplemental therapeutics #4
      p97 atra #4
      dap5 p97 expression #4
      azd2281 autophagy #4
      azd2281 induced #4
      pathway dap5 #4
      granulocytes promyelocytic #4
      induced dap5 #4
      azd228 #4
      brca1 allelic loss #4
      dap5 p97 atra #4
      melanoma zyflamend #4
      mda231 orthotopic #5
      p70s6 shrna #5
      lines azd2281 #5
      pdcd4 focal #5
      pdcd4 cyclin d1 #5
      p70s6 breast #5
      hla alopecia #5
      mda231 p70s6 #5
      p70s6k pdcd4 #5
      cyclin d1 pdcd4 #5
      mda231 control #5
      doi101038 mtna201345 #6
      nanotherapeutics inhibits #6
      therapeutic silencing bcl2 #6
      bcl2 systemically #6
      robust persistent silencing #6
      highly regulated forms #6


      Prominent publications by Ugur Akar

      KOL-Index: 14727

      Programmed cell death-4 (PDCD4) is a recently discovered tumor suppressor protein that inhibits protein synthesis by suppression of translation initiation. We investigated the role and the regulation of PDCD4 in the terminal differentiation of acute myeloid leukemia (AML) cells. Expression of PDCD4 was markedly up-regulated during all-trans retinoic acid (ATRA)-induced granulocytic differentiation in NB4 and HL60 AML cell lines and in primary human promyelocytic leukemia (AML-M3) and ...

      Known for Tumor Suppressor | Pdcd4 Expression | Granulocytic Differentiation | Programmed Cell | Myeloid Leukemia
      KOL-Index: 13996

      PARP inhibitors are considered promising anticancer agents and currently being tested in clinical trials in hereditary breast cancer patients harboring mutations in BRCA1 and BRCA2 genes. In this study, we investigated the antiproliferative effects and mechanism of PARP inhibitors ABT-888 (Veliparib), BSI-201 (Iniparib) and AZD228 (Olaparib) in breast cancer cell lines with BRCA1 or BRCA2 mutations and 9 different BRCA wild-type cell lines with BRCA1 allelic loss. We found that AZD2281 ...

      Known for Parp Inhibitor | Breast Cancer | Brca Mutations | Tnbc Cells | Growth Inhibition
      KOL-Index: 11018

      Elevated expression of tissue transglutaminase (TG2) in cancer cells has been implicated in the development of drug resistance and metastatic phenotypes. However, the role and the mechanisms that regulate TG2 expression remain elusive. Here, we provide evidence that protein kinase Cdelta (PKCdelta) regulates TG2 expression, which in turn inhibits autophagy, a type II programmed cell death, in pancreatic cancer cells that are frequently insensitive to standard chemotherapeutic agents. ...

      Known for Pancreatic Cancer Cells | Tissue Transglutaminase | Tg2 Expression | Protein Kinase | Growth Inhibition
      KOL-Index: 9908

      More than 75% of breast cancers that develop in BRCA1 mutation carriers are triple-negative breast cancers (TNBC). The aim of this study was to compare the recurrence-free survival (RFS) and overall survival (OS) in high-risk patients with TNBC with and without deleterious BRCA1/2 mutations. A total of 227 women with TNBC who were referred for genetic counseling and underwent BRCA genetic testing between 1997 and 2010 were included in the study. The relationships between clinical ...

      Known for Brca Mutations | Negative Breast | Genetic Counseling | Tnbc Adult | Tumor Characteristics
      KOL-Index: 9731

      Overexpression of p70S6K in breast cancer patients is associated with aggressive disease and poor prognosis. Recent studies showed that patients with breast cancer with increased p70S6K phosphorylation had poor survival and increased metastasis. The purpose of our study was to determine whether knockdown of p70S6K would inhibit cell growth, invasion, and metastasis in breast cancer. We therefore stably knocked down p70S6K expression in MDA-231, a highly metastatic breast cancer cell ...

      Known for Breast Cancer | Cell Growth | Role P70s6k | Cyclin D1 | Focal Adhesion
      KOL-Index: 7959

      The epidermal growth factor receptor (EGFR) signaling pathway has emerged as a promising target for cancer therapy. EGFR tyrosine kinase inhibitors (TKI) such as erlotinib have been approved for cancer treatment but have shown very limited activity in breast cancer patients. Clarifying the molecular mechanism underlying resistance to EGFR TKIs could lead to more effective treatment against breast cancer. We previously reported that the sensitivity of breast cancer cells to erlotinib is ...

      Known for Breast Cancer | Stathmin Gene | P27 Phosphorylation | Growth Factor | Erlotinib Resistance
      KOL-Index: 7756

      Clear cell carcinoma (CCC) of the ovary tends to show resistance to standard chemotherapy, which results in poor survival for patients with CCC. Developing a novel therapeutic strategy is imperative to improve patient prognosis. Epidermal growth factor receptor (EGFR) is frequently expressed in epithelial ovarian cancer. One of the major downstream targets of the EGFR signaling cascade is extracellular signal-related kinase (ERK). PEA-15, a 15-kDa phosphoprotein, can sequester ERK in the ...

      Known for Clear Cell | Xenograft Model | Mek1 2 | Map Kinase | Mice Mice
      KOL-Index: 7344

      Inherited polymorphisms in the genes controlling the cell cycle or functioning in the DNA repair mechanisms may impair their function and contribute to genetic susceptibility. Abnormalities in the DNA repair have been reported in head and neck cancer. The XRCC1 gene functions in singlestrand break and base excision repair processes. In this study, two polymorphisms of the XRCC1 gene, Arg194Trp and Arg399G1n were investigated in 95 patients with head and neck carcinoma. The polymorphic ...

      Known for Dna Repair | Neck Cancer | Xrcc1 Gene | Disease Genotype Head | Aged Polymorphism
      KOL-Index: 6597

      Bcl-2 is overexpressed in about a half of human cancers and 50-70% of breast cancer patients, thereby conferring resistance to conventional therapies and making it an excellent therapeutic target. Small interfering RNA (siRNA) offers novel and powerful tools for specific gene silencing and molecularly targeted therapy. Here, we show that therapeutic silencing of Bcl-2 by systemically administered nanoliposomal (NL)-Bcl-2 siRNA (0.15 mg siRNA/kg, intravenous) twice a week leads to ...

      Known for Therapeutic Silencing | Bcl2 Sirna | Breast Cancers | Xenograft Tumors | Tumor Growth

      HLA in alopecia areata

      KOL-Index: 5608

      BACKGROUND: The aim of this study was to investigate the human leukocyte antigen (HLA) characteristics of Turkish alopecia areata patients, and the correlation of the HLA profile with age of onset, severity and duration of the disease, presence of ophiasis, and family history.

      METHODS: A total of 88 patients with alopecia areata, alopecia totalis, or alopecia universalis were compared with 100 healthy controls. HLA typing was performed by the Terasaki microlymphocytotoxicity ...

      Known for Alopecia Areata | Hla Profile | Illness Turkey | Age Onset | Patients Control
      KOL-Index: 5008

      BACKGROUND: Recent reports indicated a significant association between fixed drug eruption (FDE) and HLA class I antigens. A strong correlation was found between B22 antigen and feprazone-induced FDE.

      OBJECTIVE: Our aim was to investigate the association between HLA class I antigens and FDE in Turkey, a country where feprazone is not on the market and trimethoprim-sulfamethoxazole is most often the offending drug.

      METHODS: HLA class I typing was performed by lymphocytotoxicity assay in ...

      Known for Fixed Drug Eruption | Hla Class | Trimethoprim Sulfamethoxazole | Oral Provocation | Drug Combination
      KOL-Index: 4654

      The selective estrogen receptor modulators (SERM), Tamoxifen and raloxifen reduce risk breast cancer. Patient acceptance of SERMs for breast cancer prevention is low due to toxicities. New agents with a better toxicity profile are needed. Aromatase inhibitors (AI) reduce the risk of contralateral breast cancer and risk of new breast cancer in high risk women. However, the mechanism by which AIs reduce breast risk is not known. Surrogate biomarkers are needed to evaluate the effect of ...

      Known for Breast Cancer | Women Increased Risk | Biomarker Modulation | Insulinlike Growth Factor | Igfbp1 Igfbp3
      KOL-Index: 4233

      Translation initiation and activity of eukaryotic initiation factor-alpha (eIF2α), the rate-limiting step of translation initiation, is often overactivated in malignant cells. Here, we investigated the regulation and role of eIF2α in acute promyelocytic (APL) and acute myeloid leukemia (AML) cells in response to all-trans retinoic acid (ATRA) and arsenic trioxide (ATO), the front-line therapies in APL. ATRA and ATO induce Ser-51 phosphorylation (inactivation) of eIF2α, through the ...

      Known for Translation Initiation | Acute Myeloid Leukemia | Malignant Cells | Ratelimiting Step | Protein Expression

      Key People For Pancreatic Cancer Cells

      Top KOLs in the world
      Ahmedin M Jemal
      united states breast cancer addis ababa
      Rebecca L Siegel
      united states colorectal cancer incidence rates
      Ralpha H Hruban†
      pancreatic cancer gene expression tumor carcinoma
      Helmut M Friess†
      pancreatic cancer chronic pancreatitis growth factor
      James L Abbruzzese
      pancreatic cancer hepatocellular carcinoma united states
      Anirban Maitra
      pancreatic cancer precursor lesions early detection

      Ugur Akar:Expert Impact

      Concepts for whichUgur Akarhas direct influence:Pancreatic cancer cells,  Translation initiation,  Tissue transglutaminase,  Breast cancer,  Therapeutic silencing,  Leukemia cells,  Cancer cells,  Small interfering.

      Ugur Akar:KOL impact

      Concepts related to the work of other authors for whichfor which Ugur Akar has influence:Breast cancer,  Cell death,  Alopecia areata,  Tissue transglutaminase,  Brca1 mutation,  Apoptosis autophagy,  Hla class.



      Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

      Department of Breast Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX. | Department of Breast Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA | Department of Breast Medic

    Download on the App StoreGet it on Google Play

    Copyright © 2023 - KOL means Key Opinion Leaders .

    KOL does not provide medical advice, diagnosis or treatment.